ONYX-015, the first tumor-selective adenovirus to undergo clinical evaluation, carries a deletion in the E1B-55K gene, which limits replication to p53-deficient tumor cells while sparing normal cells with intact p53 (31). The gene discussed is TP53; the disease is neoplasm.